Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a single-arm, multicenter, exploratory clinical study to evaluate the safety and
efficacy of the combination of etoposide, cytarabine and PEG-rhG-CSF (EAP regimen) on
hematopoietic stem cell mobilization in poor mobilization patients with hematological
malignancies. All eligible patients will receive EAP regimen treatment, then the number of
CD34+ cells and white blood cells will be monitoring. When the collection standard is met,
hematopoietic stem cell collection will be started.
Phase:
Phase 4
Details
Lead Sponsor:
The Affiliated People's Hospital of Ningbo University